Aspirin-triggered 15-epi-lipoxin A4 signals through FPR2/ALX in vascular smooth muscle cells and protects against intimal hyperplasia after carotid ligation
Open accessAbstract
The benefit of aspirin is well established in cardiovascular prevention, and involves the irreversible inhibition of platelet cyclooxygenase (COX)-1 and, as a consequence, decreased thromboxane levels [1]. In addition to inhibition of platelet aggregation, aspirin may also have anti-inflammatory properties, with potential additional benefit in atherosclerosis prevention. Acetylation of the COX-2 enzyme by aspirin directs the metabolism of polyunsaturated fatty acids (PUFAs) towards a biosynthetic pathway, which in addition involves lipoxygenase enzymes and leads to the formation of specific mediators, such as 15-epi-lipoxin A4, also referred to as aspirin-triggered lipoxin (ATL) [2].
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Lesional macrophages are the principal target of Ac2-26 in these studies, although SPMs might also interact with lesional smooth muscle cells and endothelial cells.
“Although the above data suggest that lesional macrophages are the principal target of Ac2–26 in these studies, SPMs might also interact with lesional smooth muscle cells and endothelial cells107,110.”
From Inflammation and its resolution in atherosclerosis: mediators and therapeutic opportunities (2019) · cites this paper as [110]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Pro-resolving lipid mediators are leads for resolution physiology
Serhan, C. N. (2014) · Nature · doi:10.1038/nature13479 · Cited by 3,041 · see citing works
Dufton, N., Hannon, R., Brancaleone, V., Dalli, J., Patel, H., Gray, M., D’Acquisto, F., Buckingham, J. C., Perretti, M., & Flower, R. J. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903526 · Cited by 298 · see citing works
Self-citationUpdate on leukotriene, lipoxin and oxoeicosanoid receptors: IUPHAR Review 7
Bäck, M., Powell, W. S., Dahlén, S., Drazen, J. M., Evans, J. F., Serhan, C. N., Shimizu, T., Yokomizo, T., & Rovati, G. E. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12665 · Cited by 217 · see citing works
Self-citationHo, K. J., Spite, M., Owens, C. D., Lancero, H., Kroemer, A. H. K., Pande, R., Creager, M. A., Serhan, C. N., & Conte, M. S. (2010) · The American Journal of Pathology · doi:10.2353/ajpath.2010.091082 · Cited by 204 · see citing works
Angioplasty triggers intracoronary leukotrienes and lipoxin A4. Impact of aspirin therapy.
Brezinski, D. A., Nesto, R. W., & Serhan, C. N. (1992) · Circulation · doi:10.1161/01.cir.86.1.56 · Cited by 193 · see citing works
Miyahara, T., Runge, S. J., Chatterjee, A., Chen, M., Mottola, G., Fitzgerald, J. M., Serhan, C. N., & Conte, M. S. (2013) · The FASEB Journal · doi:10.1096/fj.12-225615 · Cited by 134 · see citing works
The role of the FPR2/ALX receptor in atherosclerosis development and plaque stability
Petri, M. H., Laguna-Fernández, A., Gonzalez-Diez, M., Paulsson-Berne, G., Hansson, G. K., & Bäck, M. (2015) · Cardiovascular Research · doi:10.1093/cvr/cvu224 · Cited by 125 · see citing works
Self-citationNeutrophil-Derived Cathelicidin Protects from Neointimal Hyperplasia
Soehnlein, O., Wantha, S., Simsekyilmaz, S., Döring, Y., Megens, R. T. A., Mause, S. F., Drechsler, M. D., Smeets, R., Weinandy, S., Schreiber, F., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002531 · Cited by 113 · see citing works
Hlawaty, H., Jacob, M., Louedec, L., et al. (2009) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.108.181750 · Cited by 51 · see citing works
Petri, M. H., Tellier, C., Michiels, C., et al. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.10.078 · Cited by 28 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Inflammation and its resolution in atherosclerosis: mediators and therapeutic opportunities
Bäck, M., Yurdagul, A., Tabas, I., Öörni, K., & Kovanen, P. T. (2019) · Nature Reviews Cardiology · doi:10.1038/s41569-019-0169-2 · Cited by 1,341 · see citing works
Self-citationAnnexin A1 Counteracts Chemokine-Induced Arterial Myeloid Cell Recruitment
Drechsler, M., de Jong, R., Rossaint, J., Viola, J. R., Leoni, G., Wang, J. M., Grommes, J., Hinkel, R., Kupatt, C., Weber, C., et al. (2015) · Circulation Research · doi:10.1161/circresaha.116.305825 · Cited by 150 · see citing works
Petri, M. H., Laguna‐Fernandez, A., Arnardottir, H., Wheelock, C. E., Perretti, M., Hansson, G. K., & Bäck, M. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13707 · Cited by 120 · see citing works
Self-citationThul, S., Labat, C., Temmar, M., Benetos, A., & Bäck, M. (2017) · European Journal of Preventive Cardiology · doi:10.1177/2047487317694464 · Cited by 81 · see citing works
Self-citationMai, J., Liu, W., Fang, Y., Zhang, S., Qiu, Q., Yang, Y., Wang, X., Huang, T., Zhang, H., Xie, Y., et al. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.09.025 · Cited by 34 · see citing works
- Authors
- Petri, M. H., Laguna-Fernandez, A., Tseng, C.-N., Hedin, U., Perretti, M., & Bäck, M.
- Affiliations
- Karolinska Institutet (SE)
- Queen Mary University of London (GB)
- Karolinska University Hospital (SE)
- Corresponding author
- Bäck, Magnus
- Venue
- International Journal of Cardiology
- Publisher
- Elsevier BV
- Published
- 2015-01
- Volume
- 179
- Pages
- 370-372
- ISSN
- 0167-5273 (ISSN-L)
- PMC
- PMC4274317
- OpenAlex
- W2120591360
- Cited by
- 60
- References
- 10
- Citations by year
- 2026: 2 · 2025: 3 · 2023: 4 · 2022: 11 · 2021: 1 · 2020: 7 · 2019: 4 · 2018: 10 · 2017: 7 · 2016: 4 · 2015: 6 · 2014: 1
- FWCI
- 5.59
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- International Journal of Cardiology (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Queen Mary Research Online (Queen Mary University of London) (submittedVersion)
- Funders
- Wellcome Trust
- Stockholms Läns Landsting (20120297)
- Vetenskapsrådet (2011-02988, 20120827, 20120474)
- Topics
- Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Eicosanoids and Hypertension Pharmacology
- Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
- Keywords
- FPR2/ALX, vascular smooth muscle cells, intimal hyperplasia, carotid artery ligation, aspirin, lipoxygenase, polyunsaturated fatty acids, atherosclerosis, anti-inflammatory activity
- MeSH terms
- Animals, Anti-Inflammatory Agents, Non-Steroidal, Aspirin, Humans, Hyperplasia, Muscle, Smooth, Vascular, Tunica Intima, Mice, Knockout, Myocytes, Smooth Muscle, Receptors, Formyl Peptide, Lipoxins, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
